Resources
58 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 4/19/2024
April is Alcohol Awareness Month. This month offers a time to raise awareness and understanding of alcohol use and misuse. Resources and support is available for individuals struggling with alcohol use. In addition, the Substance Abuse and Mental Health Services Administration provides a social media toolkit for communities to utilize.
Posted 11/9/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) published Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants in 2018. The National Center on Substance Abuse and Child Welfare (NCSACW) developed companion materials that offer information and strategies to support pregnant and parenting people with substance use disorders (SUDs) in the child welfare system.
Posted 10/23/2023 (updated 5/24/2024)
Using data from 77 harm reduction programs in 25 US states, researchers found that 12-15% of powder methamphetamine and powder cocaine also contained fentanyl although the prevalence varied geographically. Prevalence of fentanyl in crystal methamphetamine and crack cocaine was lower. Heroin and xylazine were also found in unregulated stimulants. Xylazine reduced the ability to detect fentanyl.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/26/2023 (updated 3/28/2024)
This session covered strategies for successfully attracting and finding candidates, including how to create an effective and compelling job ad and website; developing a sourcing plan; leveraging social media; and incorporating diversity, equity, and inclusion in your marketing efforts.
Posted 7/26/2023 (updated 3/28/2024)
Drake Cooper partnered with JBS International, Inc. (JBS) to help grantees increase their capacity and sustainability through campaign marketing materials built to combat community stigma surrounding substance use disorder (SUD) and OUD.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.